HK1007881A1 - Sugar modified nucleosides and their use for synthesis of oligonucleotides - Google Patents

Sugar modified nucleosides and their use for synthesis of oligonucleotides

Info

Publication number
HK1007881A1
HK1007881A1 HK98109044A HK98109044A HK1007881A1 HK 1007881 A1 HK1007881 A1 HK 1007881A1 HK 98109044 A HK98109044 A HK 98109044A HK 98109044 A HK98109044 A HK 98109044A HK 1007881 A1 HK1007881 A1 HK 1007881A1
Authority
HK
Hong Kong
Prior art keywords
oligonucleotides
synthesis
modified nucleosides
sugar modified
sugar
Prior art date
Application number
HK98109044A
Other languages
English (en)
Inventor
Guangyi Wang
Kandasamy Ramasamy
Wilfried Seifert
Original Assignee
Icn Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals
Publication of HK1007881A1 publication Critical patent/HK1007881A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK98109044A 1994-11-02 1998-07-09 Sugar modified nucleosides and their use for synthesis of oligonucleotides HK1007881A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/333,545 US5681940A (en) 1994-11-02 1994-11-02 Sugar modified nucleosides and oligonucleotides
PCT/US1995/014600 WO1996014329A1 (en) 1994-11-02 1995-11-02 Sugar modified nucleosides and their use for synthesis of oligonucleotides

Publications (1)

Publication Number Publication Date
HK1007881A1 true HK1007881A1 (en) 1999-04-30

Family

ID=23303253

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98109044A HK1007881A1 (en) 1994-11-02 1998-07-09 Sugar modified nucleosides and their use for synthesis of oligonucleotides

Country Status (17)

Country Link
US (3) US5681940A (pl)
EP (1) EP0789706A4 (pl)
JP (1) JP3633626B2 (pl)
KR (1) KR100274331B1 (pl)
CN (1) CN1122040C (pl)
AU (1) AU690394B2 (pl)
CA (2) CA2202280C (pl)
CZ (1) CZ293731B6 (pl)
HK (1) HK1007881A1 (pl)
HU (1) HUT77516A (pl)
MX (1) MX9703192A (pl)
PL (1) PL184378B1 (pl)
RU (1) RU2145964C1 (pl)
SI (1) SI9520113A (pl)
SK (1) SK54897A3 (pl)
UA (1) UA45362C2 (pl)
WO (1) WO1996014329A1 (pl)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743902B1 (en) * 1994-11-02 2004-06-01 Valeant Pharmaceuticals International Sugar modified nucleosides
AU674639B2 (en) * 1994-12-13 1997-01-02 Akira Matsuda 3'-substituted nucleoside derivatives
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20040161844A1 (en) * 1996-06-06 2004-08-19 Baker Brenda F. Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20040171030A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
US20050118605A9 (en) * 1996-06-06 2005-06-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040161777A1 (en) * 1996-06-06 2004-08-19 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US20040171032A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Non-phosphorous-linked oligomeric compounds and their use in gene modulation
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6576752B1 (en) 1997-02-14 2003-06-10 Isis Pharmaceuticals, Inc. Aminooxy functionalized oligomers
US6127533A (en) * 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US20050282198A1 (en) * 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
CN1273476C (zh) 1997-09-12 2006-09-06 埃克西康有限公司 寡核苷酸类似物
WO2000056749A1 (en) 1999-03-24 2000-09-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services N-acylphosphoramidites and their use in oligonucleotide synthesis
US6900186B1 (en) * 1999-06-21 2005-05-31 Murdock Children's Research Institute Method for the prophylaxis and/or treatment of medical disorders
US20020142982A1 (en) * 1999-09-02 2002-10-03 Timothy Hla Method for regulating angiogenesis
BR0111145B1 (pt) * 2000-05-26 2013-06-04 mÉtodos para purificar dna de filamento duplo a partir de uma soluÇço contendo o dna de filamento duplo misturado com outros componentes.
GB0013276D0 (en) * 2000-06-01 2000-07-26 Amersham Pharm Biotech Uk Ltd Nucleotide analogues
US6869764B2 (en) 2000-06-07 2005-03-22 L--Cor, Inc. Nucleic acid sequencing using charge-switch nucleotides
WO2001094609A1 (en) 2000-06-07 2001-12-13 Li-Cor, Inc. Charge-switch nucleotides
US6936702B2 (en) 2000-06-07 2005-08-30 Li-Cor, Inc. Charge-switch nucleotides
ES2299561T3 (es) 2001-01-26 2008-06-01 Btg International Limited Analogo de bencilamina.
AU2002258997A1 (en) * 2001-04-24 2002-11-05 Li-Cor, Inc. Polymerases with charge-switch activity and methods of generating such polymerases
US7118907B2 (en) * 2001-06-06 2006-10-10 Li-Cor, Inc. Single molecule detection systems and methods
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP1438054A4 (en) * 2001-09-28 2006-07-26 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
US7355037B2 (en) * 2001-12-03 2008-04-08 The United States Of America As Represented By The Department Of Health And Human Services Thermolabile hydroxyl protecting groups and methods of use
GB0129012D0 (en) 2001-12-04 2002-01-23 Solexa Ltd Labelled nucleotides
US11008359B2 (en) 2002-08-23 2021-05-18 Illumina Cambridge Limited Labelled nucleotides
SI3587433T1 (sl) 2002-08-23 2020-08-31 Illumina Cambridge Limited Modificirani nukleotidi
US7414116B2 (en) 2002-08-23 2008-08-19 Illumina Cambridge Limited Labelled nucleotides
WO2004044132A2 (en) * 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP1562971B1 (en) * 2002-11-05 2014-02-12 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP1625140A4 (en) * 2002-12-23 2008-06-18 Dynavax Tech Corp BRANCHED IMMUNOMODULAR COMPOUNDS AND METHOD OF USE THEREOF
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2006065751A2 (en) * 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
NZ564146A (en) * 2005-05-25 2011-02-25 Tina Holding Aps Stable and selective formation of Hoogsteen-type triplexes and duplexes using twisted intercalating nucleic acids (TINA) and process for the preparation of TINA
EP2013344B1 (en) 2006-05-03 2012-08-29 Baltic Technology Development, Ltd. Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
EP2028272B1 (en) * 2006-06-06 2014-01-08 Panasonic Corporation Method of modifying nucleotide chain
WO2008137758A2 (en) 2007-05-04 2008-11-13 Mdrna, Inc. Amino acid lipids and uses thereof
EP3643782A1 (en) 2008-02-11 2020-04-29 Phio Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
US20100015708A1 (en) * 2008-06-18 2010-01-21 Mdrna, Inc. Ribonucleic acids with non-standard bases and uses thereof
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
US8664189B2 (en) 2008-09-22 2014-03-04 Rxi Pharmaceuticals Corporation RNA interference in skin indications
EP2902013A1 (en) 2008-10-16 2015-08-05 Marina Biotech, Inc. Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
EP2358398A2 (en) 2008-10-24 2011-08-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
US20120059045A1 (en) 2008-10-24 2012-03-08 Isis Pharmaceuticals, Inc. Methods of using oligomeric compounds comprising 2'-substituted nucleosides
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
KR20110128947A (ko) * 2009-03-20 2011-11-30 앨리오스 바이오파마 인크. 치환된 뉴클레오시드 및 뉴클레오티드 유사체
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
WO2011119852A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
CN105131067B (zh) 2010-03-24 2019-02-19 雷克西制药公司 皮肤与纤维化症候中的rna干扰
EP3091027B1 (en) 2010-04-28 2018-01-17 Ionis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
KR101869570B1 (ko) 2010-04-28 2018-06-20 아이오니스 파마수티컬즈, 인코포레이티드 변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
AU2011305655B2 (en) 2010-09-22 2015-11-05 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012040124A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
AP2014007796A0 (en) 2011-12-22 2014-07-31 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
JP6570447B2 (ja) 2012-10-15 2019-09-04 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｃ９ｏｒｆ７２発現を調節するための組成物
EP2906697A4 (en) 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc METHODS OF MONITORING C9ORF72 EXPRESSION
EP2915815B1 (en) * 2012-10-31 2018-01-17 Takeda Pharmaceutical Company Limited New modified nucleic acid
EP3388442A1 (en) 2013-03-15 2018-10-17 Illumina Cambridge Limited Modified nucleosides or nucleotides
NZ631552A (en) 2013-05-01 2017-02-24 Ionis Pharmaceuticals Inc Compositions and methods for modulating hbv expression
US9670492B2 (en) * 2013-08-28 2017-06-06 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (PKK) expression
CN105637090B (zh) 2013-10-11 2020-10-16 Ionis制药公司 用于调节c9orf72表达的组合物
JP6772062B2 (ja) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 癌の免疫療法
WO2015106128A2 (en) * 2014-01-09 2015-07-16 Alnylam Pharmaceuticals, Inc. MODIFIED RNAi AGENTS
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
SG10201912897UA (en) 2014-01-16 2020-02-27 Wave Life Sciences Ltd Chiral design
EP3137119B1 (en) 2014-04-28 2020-07-01 Phio Pharmaceuticals Corp. Methods for treating cancer using a nucleic acid targeting mdm2
AU2015252917B2 (en) 2014-05-01 2019-09-26 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating PKK expression
CN106232804B (zh) * 2014-05-01 2019-10-25 Ionis制药公司 用于调节补体因子b表达的组合物和方法
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
CN104211741B (zh) * 2014-09-05 2017-05-31 河南师范大学 一种氘代核苷亚磷酰胺单体的合成方法
CA2978103A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CN108135923B (zh) 2015-07-06 2021-03-02 菲奥医药公司 靶向超氧化物歧化酶1（sod1）的核酸分子
CN109563509B (zh) 2015-10-19 2022-08-09 菲奥医药公司 靶向长非编码rna的减小尺寸的自递送核酸化合物
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
CA3047373A1 (en) 2016-12-16 2018-06-21 Gifu University Nucleoside derivative and use thereof
JP7231147B2 (ja) * 2017-06-29 2023-03-01 国立大学法人東海国立大学機構 Ｒｎａ導入試薬及びその利用
JP7173467B2 (ja) * 2017-10-31 2022-11-16 ヤマサ醤油株式会社 ヌクレオシド誘導体及びその利用
CN111868244A (zh) * 2018-03-20 2020-10-30 国立大学法人东京工业大学 降低了毒性的反义寡核苷酸
MA55556A (fr) 2019-04-02 2022-02-09 Aligos Therapeutics Inc Composés ciblant prmt5
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190969A (en) * 1988-12-20 1993-03-02 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services 2,3-epoxy derivatives as anti retrovital chemotherapeutic agents
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
FR2687679B1 (fr) * 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
HU9501994D0 (en) * 1993-03-31 1995-09-28 Sterling Winthrop Inc Novel 5'-substituted nucleosides and oligomers produced therefrom
US5446137B1 (en) * 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides

Also Published As

Publication number Publication date
CZ129197A3 (en) 1997-10-15
MX9703192A (es) 1997-12-31
HUT77516A (hu) 1998-05-28
JP3633626B2 (ja) 2005-03-30
AU4152596A (en) 1996-05-31
RU2145964C1 (ru) 2000-02-27
PL319944A1 (en) 1997-09-01
JPH10506915A (ja) 1998-07-07
US5681940A (en) 1997-10-28
KR100274331B1 (ko) 2000-12-15
CZ293731B6 (cs) 2004-07-14
AU690394B2 (en) 1998-04-23
EP0789706A1 (en) 1997-08-20
PL184378B1 (pl) 2002-10-31
CA2202280C (en) 2000-08-15
CN1122040C (zh) 2003-09-24
US6191266B1 (en) 2001-02-20
WO1996014329A1 (en) 1996-05-17
SK54897A3 (en) 1997-09-10
EP0789706A4 (en) 1999-08-11
US5712378A (en) 1998-01-27
CN1170412A (zh) 1998-01-14
CA2202280A1 (en) 1996-05-17
UA45362C2 (uk) 2002-04-15
SI9520113A (sl) 1998-06-30
CA2307311A1 (en) 1996-05-17

Similar Documents

Publication Publication Date Title
HK1007881A1 (en) Sugar modified nucleosides and their use for synthesis of oligonucleotides
GB9501465D0 (en) Nucleoside phosphorothioate derivatives,synthesis and use thereof
AU7153098A (en) Method of synthesis of 2-O-substituted pyrimidine nucleosides and oligonucleotides
AU1436995A (en) Synthesis of propargyl modified nucleosides and phosphoramidites and their incorporation into defined sequence oligonucleotides
AU2657095A (en) Synthesis of oligonucleotides
IL116831A0 (en) Guanine derivatives its preparation and use
PL327443A1 (en) Methods of and compositions for effecting synthesis of dioxolanic nucleosides of beta configuration
HUP9802445A3 (en) Liposomal oligonucleotide compositions and process for inhibiting the human raf
GB9413724D0 (en) Therapeutic nucleosides
AP9500735A0 (en) Conttolled release dosage forms of azithromycin
IL114018A0 (en) Genes for the synthesis of antipathogenic substances their preparation and their use
GB9524938D0 (en) Modification of starch synthesis in plants
GB9526560D0 (en) Use of 2-Amino-Heterocycles
EP0731808A4 (en) BOR CLUSTER CONTAINING NUCLEOSIDES AND OLIGONUCLEOSIDES
IL114887A0 (en) Oxypurine nucleosides and their congeners and acyl derivatives thereof for improvement of hematopoiesis
EG21286A (en) Blends of organosillane compounds and their use
EP0821001A4 (en) AMIDITY DERIVATIVES AND OLIGONUCLEOTIDE DERIVATIVES
GB9624745D0 (en) Ornamental structure of product
ZA96725B (en) Use of phenyclyclohexylcarboxamides
GB9518154D0 (en) Oligonucleotides and their use
PL316985A1 (en) Derivatives of adenosine
HUP9801576A3 (en) Process for the synthesis of nucleoside analogues and the intermediers
HUP0100879A3 (en) Nucleosides and their use for preparation of antiviral medicaments
HUP9902417A3 (en) Acylated enol derivatives of alfa-ketoesters and alfa-ketoamides
EP0458519A3 (en) Synthesis of nucleotide and nucleoside derivatives

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20071102